CRBU · Caribou Biosciences, Inc. · Documents

$0.38 -0.01 (-2.69%) At close · Nov 12

Russell 2000 member Rebalance outlook locked

Market Cap

$41.08M

108.04M

Volume · Nov 12 1.54M Avg daily vol (3M) 2.72M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

2024

May 7

Current report 8-K

Financial results

May 7

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $2.43M ▼ 30.6% Net loss $41.23M Diluted EPS -$0.46

Apr 25

Proxy statement DEF 14A

Proxy statement

Apr 25

Annual report to holders ARS

Annual report to holders

Apr 25

Proxy statement DEFA14A

Proxy statement

Apr 4

Current report 8-K

Regulation FD disclosure, Other events

Mar 11

Current report 8-K

Financial results

Mar 11

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $34.48M ▲ 148.9% Net loss $102.07M Diluted EPS -$1.38

Jan 8

Current report 8-K Events of Jan 7

Regulation FD disclosure, Other events

2023

Dec 22

Current report 8-K

Director or officer change, or executive pay

Dec 12

Current report 8-K Events of Dec 11

Director or officer change, or executive pay, Regulation FD disclosure, Other events

Nov 17

Quarterly report 10-Q/A Ended Mar 31

Quarterly report for the period ended Mar 31, 2023

Nov 17

Quarterly report 10-Q/A Ended Jun 30

Quarterly report for the period ended Jun 30, 2023

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $23.66M ▲ 616.4% Net loss $10M Diluted EPS -$0.12

Oct 18

Current report 8-K

Regulation FD disclosure, Other events

Sep 26

Current report 8-K

Ended a material agreement

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $3.76M ▼ 10.4% Net loss $29.52M Diluted EPS -$0.48

Jul 17

Current report 8-K Events of Jul 13

Entered into a material agreement

Jul 14

Current report 8-K/A Events of Jul 13

Other events

Jul 13

Current report 8-K

Other events

Jul 13

Current report 8-K

Financial results, Regulation FD disclosure

Jul 6

Current report 8-K Events of Jun 29

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure, Other events

Jun 16

Current report 8-K Events of Jun 15

Shareholder vote results

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $3.5M ▲ 31.5% Net loss $28.04M Diluted EPS -$0.46

Apr 28

Proxy statement DEF 14A

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Apr 28

Proxy statement DEFA14A

Proxy statement

Apr 4

Current report 8-K

Regulation FD disclosure, Other events

Mar 29

Current report 8-K

Regulation FD disclosure, Other events

Mar 29

Current report 8-K

Regulation FD disclosure, Other events

Mar 24

Current report 8-K

Other events

Mar 9

Current report 8-K

Financial results

Mar 9

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $13.85M ▲ 44.3% Net loss $99.42M Diluted EPS -$1.64

2022

Dec 16

Current report 8-K Events of Dec 15

Director or officer change, or executive pay

Dec 12

Current report 8-K

Regulation FD disclosure, Other events

Nov 29

Current report 8-K

Regulation FD disclosure, Other events

Nov 21

Current report 8-K

Regulation FD disclosure, Other events

Nov 8

Current report 8-K

Financial results

Nov 8

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $3.3M ▼ 16.9% Net loss $26.65M Diluted EPS -$0.44

Nov 3

Current report 8-K

Regulation FD disclosure

Oct 18

Current report 8-K

Regulation FD disclosure

Sep 23

Current report 8-K/A Events of Sep 20

Shareholder vote results

Sep 22

Current report 8-K Events of Sep 21

Shareholder vote results

Aug 12

Current report 8-K Events of Aug 9

Entered into a material agreement

Aug 11

Proxy statement DEF 14A

Proxy statement

Aug 11

Proxy statement DEFA14A

Proxy statement

Aug 11

Proxy statement DEFA14A

Proxy statement

Showing 51–100 of 127 documents

Key facts CIK 1619856 CUSIP 142038108 13F (30d) 94 filings 81 filers Visit website Investor relations